BioPharma Media

* Personalized cancer vaccines are the future of cancer treatment.
* These vaccines are tailored to the tumor specificity of each patient and can be manufactured quickly.
* The first individualized oncovaccine adhering to the concept of precision medicine will be available in 2025.
* Successful treatment of melanoma and head and neck cancer has already been demonstrated.
* Lung, kidney, bladder and non-melanoma skin cancers are next in line.

Moderna mRNA-4157: Personalized Cancer Vaccine That Really Works • BioPharma Media mRNA technologies paint an optimistic future in cancer treatment.

Japan’s & Co. has offered ( ), a new drug for treating infection caused by the coronavirus.

Xocova works just like the extremely popular ( + ) from by suppressing viral replication.

While Paxlovid needs to be taken twice a day, Xocova only once.
In addition, the Japanese is free of the problem of drug interaction: Treatment with Paxlovid in some cases requires temporary cessation of taking other medicines.

And perhaps most importantly, Xocova is allowed to treat patients regardless of the presence of risk factors for progression of the infection to a severe form.

Xocova: Powerful New Japanese Pill for Coronavirus Treatment • BioPharma Media Ensitrelvir by Shionogi & Co. is a highly effective antiviral drug that works just as well as Pfizer’s Paxlovid.